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87 hours and 32 minutes. The staff spent on average 85 minutes in IV-PCA related 
activities, of which the nurse spent 98%. The average cost, including material and 
staff, for 24-hour usage of IV-PCA was a58.38. The patients thought that their pain 
was under control and they did not think it could be treated better, but they had some 
problem with pain when breathing or expectorating. According to the staff the IV-PCA 
system was easy to use for the patient but hindered their mobilization. CONCLU-
SIONS: IV-PCA involves many different roles and activities and intertwined sub pro-
cesses. Therefore the whole system is complex and resource demanding. Comparisons 
of the results from similar studies at other hospitals will be very useful when optimiz-
ing the process.
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OBJECTIVES: Sickle cell disease (SCD) is an inherited disorder predominantly affect-
ing people of African descent, and is characterized by the production of defective 
hemoglobin. Patients with SCD may experience intermittent and sometimes life-threat-
ening complications often leading to frequent hospitalizations. Hydroxyurea (HU) is 
the only pharmacologic intervention approved (in 1998) for the treatment of adult 
SCD. This study expands upon previous research (Lanzkron et al, 2006) and generates 
national estimates of changes in SCD-related hospitalization rates and associated 
resource use in the United States (US) following approval of HU. METHODS: Dis-
charge data from the 1996–2005 HCUP Nationwide Inpatient Samples for adult (q20 
years) African American (AA) patients with a primary SCD diagnosis (ICD-9-CM 
codes 282.6, 282.6x) were analyzed. Weighted, age-standardized hospitalization rates, 
and estimates of total charges and length of stay (LOS) were calculated for the 2 years 
before (1996–1997) and 8 years (1998–2005) following approval of HU. RESULTS: 
The age-standardized rate of SCD-related hospitalizations (per 10,000 2008 US adult 
AA population) has fallen appreciably from just before HU’s approval in 1997 to 
2005, from 17.3/10,000 to 13.8/10,000, a reduction of ~20%. During this period, the 
mean LOS has remained roughly unchanged (~6 days), though interestingly, mean 
total charges (in 2008 USD) incurred during an SCD-related stay have increased nearly 
65%, from $15,197 in 1997 to $25,005 in 2005. CONCLUSIONS: We examined 
changes in rates of SCD-related hospitalizations and associated outcomes among AA 
patients following approval of HU for treatment of adult SCD. We observed a general 
decrease in the rate of hospitalizations over the ﬁrst 7 years following approval of 
HU. However, little difference in LOS was seen, and total charges for this patient 
group have increased appreciably for unknown reasons. Clinicians and other decision-
makers should be aware of the impact that HU appears to have on SCD-related inpa-
tient outcomes.
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OBJECTIVES: Cognitive and neurologic dysfunction, the most common physiological 
manifestations of hyponatremia, can signiﬁcantly impair individuals’ health-related 
quality of life (HRQOL). Therapeutic correction of hyponatremia should focus not 
only on normalization of serum sodium, but improvement of patients’ functional 
utility as well. We examined the average change in utility scores from initiation of           
either tolvaptan therapy or standard of care (SOC) to day-7 and day-30 post-initiation. 
Standardized utility scores were derived from SF-12 scores from pooled SALT (Study  
of Ascending Levels of Tolvaptan in Hyponatremia) I and II data. METHODS: SF-12 
scores were mapped to the EQ-5D and utility scores were derived using methodology 
developed by Gray, et.al, 2006. Mean change from baseline was assessed for both 
tolvaptan and standard of care (SOC) patient cohorts at day-7 and day-30, quantiﬁed 
as both absolute and percent change. Differences from baseline to day-7 and day-30 
were assessed using a student’s t test. RESULTS: All patients in the SALT trials had 
a baseline serum sodium 135 mEq/L. From baseline to day-7, the mean increase in 
utility score for tolvaptan patients (n  180) was 0.084, compared to an increase of 
0.032 for patients receiving SOC (n  163) (p  0.183). A statistically signiﬁcant mean 
increase in utility was associated with tolvaptan use from baseline to day 30 post-
therapy initiation compared with SOC (p  0.005). The mean increase in utility score 
at day 30 for patients receiving tolvaptan (n  150) was 0.108, whereas utility scores 
for patients receiving SOC (n  164) had returned to baseline values by day-30, with 
a mean change from baseline of 0.001. CONCLUSIONS: Tolvaptan use for hypona-
tremia is associated with an increase in utility compared with SOC, evident at day-7 
and statistically signiﬁcant (p  0.005) at day-30. Utility for tolvaptan patients 
increased from day-7 to day-30 while those for SOC decreased to baseline during this 
period.
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OBJECTIVES: The objective of this study was to measure health state utilities associ-
ated with Immune Thrombocytopenic Purpura (ITP), as perceived by members of the 
Canadian general public. METHODS: An electronic version of the Time Trade-off 
(TTO) method was developed and administered to a sample of the general public in 
Canada. Twelve distinct health states were deﬁned based on severity of bleeding, 
presence of other adverse events, and whether treatment was with romiplostim (a new 
thrombopoietin mimetic agent) or standard of care. Results from two 24-week ran-
domized controlled phase 3 trials were used in developing health state descriptions. 
Pilot surveys were developed to ensure ease of use and to improve measurement 
characteristics of the ﬁnal survey. A sample of 813 subjects was needed for power 
0.90 and an alpha error of 0.05. Utility scores were reported as mean, median and 
range for each health state and compared using Dunn’s post-hoc test. RESULTS: After 
two pilot tests on 126 participants, 821 adults [mean age 36.4 (range 22–80) years, 
63% female] from Ontario, Canada, completed the TTO valuation survey. Mean (SD) 
utility scores ranged from 0.476 (0.271) for the most severe health state describing 
signiﬁcant bleeding to 0.633 (0.282) for the health state depicting successful treatment 
with romiplostim without bleeding. Mean differences between the most severe bleed-
ing health state and 5 other health states were statistically signiﬁcant (p  0.05 for 
each). CONCLUSIONS: The Canadian general public had decreased preference for 
the most severe ITP health states with signiﬁcant bleeding. Respondents most preferred 
ITP health states with no bleeding combined with successful treatment with romip-
lostim. The utility scores derived from these 12 health states can be used as to inform 
cost-effectiveness models of romiplostim as a treatment for ITP in Canada.
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OBJECTIVES: Phenylketonuria (PKU) and its dietary management have a substantial 
effect on quality of life (QOL) of patients and their families. There is little published 
research that quantiﬁes these effects in this orphan disease. The study explores the 
impact of PKU and its severity on QOL by eliciting utilities from a sample of general 
population. METHODS: Health state descriptions were developed for children and 
adults from the literature and expert interviews (n  3) and validated by different clini-
cians (n  3). Health states for children were: controlled (designated by target phenyl-
alanine levels) by diet or medication for severe or mild/moderate disease; uncontrolled 
irrespective of severity. Adults’ states were: controlled by diet or medication; uncon-
trolled. 100 participants across four UK centres were presented randomly with health 
state descriptions which were valued using the EQ-5D questionnaire and TTO (Time-
trade-off) exercise to produce utility values. RESULTS: For both children and adults 
health states, the highest utility was attributed to health states controlled by medicine 
for both the EQ-5D and TTO (Children: severe 0.71–0.91, mild/moderate 0.76–0.94. 
Adults: 0.79–0.83). The uncontrolled state is associated with a lower utility score 
across groups and instruments. The EQ-5D scores were lower compared to TTO 
(particularly for children where parents found difﬁculty in trading off length of life). 
The addition of a drug, adjunct to diet, had larger effect on the EQ-5D score. Utilities 
for children were higher than adults across methods CONCLUSIONS: This small 
study provides evidence of a QoL impact of phenylketonuria. In both TTO and EQ-5D 
valuations, utilities were higher in controlled compared to uncontrolled state in chil-
dren and adults. The addition of an effective drug, adjunct to diet, to control PKU 
improved utility further. This research also provides insight into the difﬁculties mea-
suring utility in orphan diseases where natural history is hard to deﬁne.
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OBJECTIVES: Hemophilia is a rare and intractable disease. Although it is a rare, the 
per-capita cost of the disease covered by health insurance budget is high. The genera-
tion of patients with inhibitors incurs higher expenses and is prone to complications. 
This study compares treatment and medication pattern by the presence of inhibitors. 
METHODS: A survey was conducted for 99 patients without inhibitors and 32 
patients with inhibitors. Age distribution of patients was similar to the actual distribu-
tion of patients. The rate and frequency of hospitalization, treatment-related tests, 
adjuvant treatment and the rate of complications were examined. In addition, patients’ 
age, drugs in use, the number of hospital visits, and the number of drug administration 
